Humacyte Inc’s recent filing unveils that its Director Dougan Brady W unloaded Company’s shares for reported $1.98 million on Jun 12 ’24. In the deal valued at $7.30 per share,271,518 shares were sold. As a result of this transaction, Dougan Brady W now holds 4,559,140 shares worth roughly $32.14 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Niklason Laura E sold 271,518 shares, generating $1,982,081 in total proceeds. Upon selling the shares at $7.30, the President, CEO and Director now owns 4,559,140 shares.
Before that, Niklason Laura E sold 358,630 shares. Humacyte Inc shares valued at $2,537,943 were divested by the President, CEO and Director at a price of $7.08 per share. As a result of the transaction, Niklason Laura E now holds 4,830,658 shares, worth roughly $34.06 million.
H.C. Wainwright initiated its Humacyte Inc [HUMA] rating to a Buy in a research note published on December 11, 2023; the price target was $6. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in mid August from “an Underweight” to “a Neutral”. Cantor Fitzgerald began covering HUMA with “an Overweight” recommendation on June 22, 2023. Piper Sandler revised its rating on May 16, 2022. It rated HUMA as “an Underweight” which previously was an “an Overweight”.
Price Performance Review of HUMA
On Friday, Humacyte Inc [NASDAQ:HUMA] saw its stock fall -2.08% to $7.05. Over the last five days, the stock has lost -3.03%. Humacyte Inc shares have risen nearly 148.24% since the year began. Nevertheless, the stocks have risen 104.64% over the past one year. While a 52-week high of $9.97 was reached on 05/31/24, a 52-week low of $1.96 was recorded on 01/17/24. SMA at 50 days reached $5.37, while 200 days put it at $3.61. A total of 1.01 million shares were traded, compared to the trading of 1.3 million shares in the previous session.
Levels Of Support And Resistance For HUMA Stock
The 24-hour chart illustrates a support level at 6.88, which if violated will result in even more drops to 6.70. On the upside, there is a resistance level at 7.25. A further resistance level may holdings at 7.44. The Relative Strength Index (RSI) on the 14-day chart is 54.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.64%. Stochastics %K at 31.01% indicates the stock is a holding.
The most recent change occurred on October 29, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $17 price target.
